Naltrexone controlled-release - Alkermes
Alternative Names: ALKS 6428; Vivitrex; Vivitrol; XL-NTX; XR-NTXLatest Information Update: 05 Jan 2024
At a glance
- Originator Alkermes
- Developer Alkermes; Alkermes plc; Cephalon; Cilag GmbH International; University of Oslo
- Class Anti-inflammatories; Antineoplastics; Antivirals; Cyclopropanes; Drug withdrawal therapies; Ethers; Eye disorder therapies; Irritable bowel syndrome therapies; Ketones; Morphinans; Non-opioid analgesics; Small molecules
- Mechanism of Action Opioid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Alcoholism; Opioid-related disorders
Most Recent Events
- 05 Jan 2024 Discontinued - Phase-III for Opioid-related disorders in Norway (IM) (Alkermes pipeline; January 2024)
- 08 Feb 2022 Alkermes terminates phase II trial in Substance-related disorders (Prevention) in Sweden (EudraCT2016-004710-95)
- 24 Feb 2021 No development reported - Phase-III for Opioid-related disorders in Norway (IM)